Related Experiment Video
Updated: Sep 9, 2026
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Biliopancreatic limb length impacts metabolic dysfunction-associated steatotic liver disease trajectories after
Christopher Tuffs1, Nadher Al Saleh2, Annette Hauenschild3
1Justus-Liebig-University Giessen, Giessen, Germany; Department of General, Visceral, Thoracic, and Transplantation Surgery, University Hospital Giessen, Giessen, Germany.
Background:
RYGB is an effective treatment option for metabolic dysfunction-associated steatotic liver disease (MASLD). The optimal configuration for the biliopancreatic limb (BPL) remains uncertain.
Objectives:
To assess whether BPL length in Roux-en-Y gastric bypass (RYGB) affects improvement in MASLD.
Setting:
University Hospital Center.
Methods:
We conducted a retrospective cohort study of adults who underwent RYGB between 2019 and 2024. Patients were dichotomized a priori by BPL length: ≈70 cm (short) versus ≥100 cm (long). Outcomes were evaluated at baseline, 3 months (3M), 1 year (1Y), and 2 years (2Y) postoperatively. Primary outcomes were MASLD-related noninvasive tests (NITs) including the Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) and Noninvasive Nonalcoholic Steatohepatitis Detection Score (NI-NASH DS).
Results:
Compared with short BPL, long BPL was associated with lower NI-NASH DS at 3M (-1.19; 95% confidence interval [CI], -1.93 to -.48; q < .01) and 1Y (-.77; 95% CI, -1.37 to -.15; q < .05) and lower NFS at 1Y (-.39; 95% CI, -.70 to -.09; q < .05) and 2Y (-.53; 95% CI, -.96 to -.10; q < .05). Glycated hemoglobin was lower at 1Y (-.10; 95% CI, -.20 to .00; q < .05) and 2Y (-.20; 95% CI, -.30 to -.00; q < .05), while total weight loss was similar. Total cholesterol and low-density lipoprotein cholesterol were lower at 1Y and 2Y. Nutritional markers were largely comparable.
Conclusions:
A longer BPL (≥100 cm) was associated with greater improvements in MASLD-related NIT trajectories at 1Y and 2Y after RYGB, with better glycemic control and similar weight loss, without evidence of nutritional deficiency.
Related Concept Videos
01:21Chronic Pancreatitis II: Pathophysiology
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...